Dr Pallavi Prasad, MD, DNB ( Nephrology)
@drpallaviprasad.bsky.social
Nephrologist 🩺 Associate Professor 📚 Bookworm 🐛 Amateur gardener 🪴Travel enthusiast 🧳
Reposted by Dr Pallavi Prasad, MD, DNB ( Nephrology)
1/10
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
November 20, 2025 at 12:34 AM
1/10
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
Reposted by Dr Pallavi Prasad, MD, DNB ( Nephrology)
T3f: #NephJC
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
November 19, 2025 at 2:41 AM
T3f: #NephJC
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA).
Do you think either has the advantage?
Reposted by Dr Pallavi Prasad, MD, DNB ( Nephrology)
T0k: #NephJC
The 96-week extension demonstrated durability:
⬇️proteinuria fell 52%
⬇️Gd-IgA1 dropped 66%
⬇️hematuria declined 75%
⬇️ annualized eGFR slope was −0.6 mL/min/1.73 m²
⚠️Safety: mild injection-site reactions and transient infections
pubmed.ncbi.nlm.nih....
The 96-week extension demonstrated durability:
⬇️proteinuria fell 52%
⬇️Gd-IgA1 dropped 66%
⬇️hematuria declined 75%
⬇️ annualized eGFR slope was −0.6 mL/min/1.73 m²
⚠️Safety: mild injection-site reactions and transient infections
pubmed.ncbi.nlm.nih....
November 19, 2025 at 2:19 AM
T0k: #NephJC
The 96-week extension demonstrated durability:
⬇️proteinuria fell 52%
⬇️Gd-IgA1 dropped 66%
⬇️hematuria declined 75%
⬇️ annualized eGFR slope was −0.6 mL/min/1.73 m²
⚠️Safety: mild injection-site reactions and transient infections
pubmed.ncbi.nlm.nih....
The 96-week extension demonstrated durability:
⬇️proteinuria fell 52%
⬇️Gd-IgA1 dropped 66%
⬇️hematuria declined 75%
⬇️ annualized eGFR slope was −0.6 mL/min/1.73 m²
⚠️Safety: mild injection-site reactions and transient infections
pubmed.ncbi.nlm.nih....
Hi everyone! Pallavi from New Delhi ! The day light saving change in #NephJC doesn't help when in India - approaching time to leave for work..will be lurking .
Excited about targeted therapeutic approaches in IgAN . No COI.
Excited about targeted therapeutic approaches in IgAN . No COI.
November 19, 2025 at 2:09 AM
Hi everyone! Pallavi from New Delhi ! The day light saving change in #NephJC doesn't help when in India - approaching time to leave for work..will be lurking .
Excited about targeted therapeutic approaches in IgAN . No COI.
Excited about targeted therapeutic approaches in IgAN . No COI.
Reposted by Dr Pallavi Prasad, MD, DNB ( Nephrology)
Check out the awesome visual abstract by @salinesolut.bsky.social
Attacking the origins of IgAN with atacicept ⚔️
www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
Attacking the origins of IgAN with atacicept ⚔️
www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
ORIGIN-3: The Visual Abstract — NephJC
Atacicept, BAFF/APRIL inhibition in IgAN
www.nephjc.com
November 18, 2025 at 12:32 PM
Check out the awesome visual abstract by @salinesolut.bsky.social
Attacking the origins of IgAN with atacicept ⚔️
www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
Attacking the origins of IgAN with atacicept ⚔️
www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract
Reposted by Dr Pallavi Prasad, MD, DNB ( Nephrology)
APRIL/BAFF inhibition: 🎯💊🩺
Trials are under way on this pathway, which promise to get to the root cause of IgAN. However, with great innovation comes…greater confusion. Sequence of treatment, cost, and side effects will need to be considered when increasing immunosuppression.
#NephJC
Trials are under way on this pathway, which promise to get to the root cause of IgAN. However, with great innovation comes…greater confusion. Sequence of treatment, cost, and side effects will need to be considered when increasing immunosuppression.
#NephJC
October 29, 2025 at 1:50 AM
APRIL/BAFF inhibition: 🎯💊🩺
Trials are under way on this pathway, which promise to get to the root cause of IgAN. However, with great innovation comes…greater confusion. Sequence of treatment, cost, and side effects will need to be considered when increasing immunosuppression.
#NephJC
Trials are under way on this pathway, which promise to get to the root cause of IgAN. However, with great innovation comes…greater confusion. Sequence of treatment, cost, and side effects will need to be considered when increasing immunosuppression.
#NephJC
Reposted by Dr Pallavi Prasad, MD, DNB ( Nephrology)
BTW super interesting basket trial from India
(Ongoing)
bsky.app/profile/hswa...
Maybe they can eventually add a povetacicept arm 😏
#NephJC
(Ongoing)
bsky.app/profile/hswa...
Maybe they can eventually add a povetacicept arm 😏
#NephJC
Ongoing late posts from @theisn.org #ISNWCN
from the high impact trial session - this was a great study design
The India ALLIANCE GRACE IgAN trial
Lead by Succeena Alexander from CMC Vellore
#NephSky
1/
from the high impact trial session - this was a great study design
The India ALLIANCE GRACE IgAN trial
Lead by Succeena Alexander from CMC Vellore
#NephSky
1/
October 29, 2025 at 1:16 AM
BTW super interesting basket trial from India
(Ongoing)
bsky.app/profile/hswa...
Maybe they can eventually add a povetacicept arm 😏
#NephJC
(Ongoing)
bsky.app/profile/hswa...
Maybe they can eventually add a povetacicept arm 😏
#NephJC
Reposted by Dr Pallavi Prasad, MD, DNB ( Nephrology)
Treatment Approach: 💊
Novel therapies for IgAN have shifted the paradigm to a bi-pronged approach.
a) Generic responses to HTN/proteinuria
b) Fundamental drivers of nephron loss by reducing the formation of aberrant IgA molecules & the maladaptive mechanisms that contribute to CKD. #NephJC
Novel therapies for IgAN have shifted the paradigm to a bi-pronged approach.
a) Generic responses to HTN/proteinuria
b) Fundamental drivers of nephron loss by reducing the formation of aberrant IgA molecules & the maladaptive mechanisms that contribute to CKD. #NephJC
October 29, 2025 at 1:18 AM
Treatment Approach: 💊
Novel therapies for IgAN have shifted the paradigm to a bi-pronged approach.
a) Generic responses to HTN/proteinuria
b) Fundamental drivers of nephron loss by reducing the formation of aberrant IgA molecules & the maladaptive mechanisms that contribute to CKD. #NephJC
Novel therapies for IgAN have shifted the paradigm to a bi-pronged approach.
a) Generic responses to HTN/proteinuria
b) Fundamental drivers of nephron loss by reducing the formation of aberrant IgA molecules & the maladaptive mechanisms that contribute to CKD. #NephJC
Reposted by Dr Pallavi Prasad, MD, DNB ( Nephrology)
Let’s recapitulate the history and evidence-based developments of IgA Nephropathy. We’ve known about the pathologic etiology for decades, however there was a huge therapeutic plateau until quite recently. 💉💊
In the last few years, new therapies are coming up rapidly.
#NephJC
In the last few years, new therapies are coming up rapidly.
#NephJC
October 29, 2025 at 12:30 AM
Let’s recapitulate the history and evidence-based developments of IgA Nephropathy. We’ve known about the pathologic etiology for decades, however there was a huge therapeutic plateau until quite recently. 💉💊
In the last few years, new therapies are coming up rapidly.
#NephJC
In the last few years, new therapies are coming up rapidly.
#NephJC
Reposted by Dr Pallavi Prasad, MD, DNB ( Nephrology)
The 2025 @kdigo.org IgAN guideline quietly redraws the map: new drugs, new thresholds, and a sense that the era of “supportive care only” is finally over #Nephsky #Medsky
✍️Summary by @thekidneywhisperer.bsky.social and
@glomerican.bsky.social
www.nephjc.com/news/igan-kd...
✍️Summary by @thekidneywhisperer.bsky.social and
@glomerican.bsky.social
www.nephjc.com/news/igan-kd...
2025 IgAN KDIGO guidelines: fresh out of press, already aging gracefully — NephJC
This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy
www.nephjc.com
October 28, 2025 at 2:06 AM
The 2025 @kdigo.org IgAN guideline quietly redraws the map: new drugs, new thresholds, and a sense that the era of “supportive care only” is finally over #Nephsky #Medsky
✍️Summary by @thekidneywhisperer.bsky.social and
@glomerican.bsky.social
www.nephjc.com/news/igan-kd...
✍️Summary by @thekidneywhisperer.bsky.social and
@glomerican.bsky.social
www.nephjc.com/news/igan-kd...
Reposted by Dr Pallavi Prasad, MD, DNB ( Nephrology)
⏩ Next #NephJC is on IgA nephropathy @kdigo.org guideline
🎨 Nice visual summary by @roxnonna23.bsky.social
www.nephjc.com/news/2025/10...
🎨 Nice visual summary by @roxnonna23.bsky.social
www.nephjc.com/news/2025/10...
KDIGO 2025 IgA guidelines - Visual Abstract — NephJC
KDIGO 2025 is here. IgAN management is evolving with precision risk tools, new therapies, and a stronger focus on kidney protection. Check out the visual abstract created by Natalia Nombera
www.nephjc.com
October 27, 2025 at 5:27 PM
⏩ Next #NephJC is on IgA nephropathy @kdigo.org guideline
🎨 Nice visual summary by @roxnonna23.bsky.social
www.nephjc.com/news/2025/10...
🎨 Nice visual summary by @roxnonna23.bsky.social
www.nephjc.com/news/2025/10...
Apart from myeloma and MGRS , what other diseases should we think of in case of increased UPCR with no albumunuria in urine analysis.
Urine alb- trace
UPCR-5.2
SIFE,SFLC - normal
@askrenal.bsky.social #askrenal
#Nephsky
Urine alb- trace
UPCR-5.2
SIFE,SFLC - normal
@askrenal.bsky.social #askrenal
#Nephsky
October 23, 2025 at 12:44 PM
Apart from myeloma and MGRS , what other diseases should we think of in case of increased UPCR with no albumunuria in urine analysis.
Urine alb- trace
UPCR-5.2
SIFE,SFLC - normal
@askrenal.bsky.social #askrenal
#Nephsky
Urine alb- trace
UPCR-5.2
SIFE,SFLC - normal
@askrenal.bsky.social #askrenal
#Nephsky
Reposted by Dr Pallavi Prasad, MD, DNB ( Nephrology)
1/10
Last #NephJC we tried to answer the question whether protein supplementation increases health related QoL 🥩💊#TenPostNephJC .
Read the article 👇
pubmed.ncbi.nlm.nih....
Last #NephJC we tried to answer the question whether protein supplementation increases health related QoL 🥩💊#TenPostNephJC .
Read the article 👇
pubmed.ncbi.nlm.nih....
October 22, 2025 at 9:05 AM
1/10
Last #NephJC we tried to answer the question whether protein supplementation increases health related QoL 🥩💊#TenPostNephJC .
Read the article 👇
pubmed.ncbi.nlm.nih....
Last #NephJC we tried to answer the question whether protein supplementation increases health related QoL 🥩💊#TenPostNephJC .
Read the article 👇
pubmed.ncbi.nlm.nih....
Reposted by Dr Pallavi Prasad, MD, DNB ( Nephrology)
⏰30 min before the #NephJC chat
Let's learn about the Gurus who paved the path to make kidney transplant “Mission Impossible to Mission Possible” with their research.
Let's learn about the Gurus who paved the path to make kidney transplant “Mission Impossible to Mission Possible” with their research.
October 1, 2025 at 12:30 AM
⏰30 min before the #NephJC chat
Let's learn about the Gurus who paved the path to make kidney transplant “Mission Impossible to Mission Possible” with their research.
Let's learn about the Gurus who paved the path to make kidney transplant “Mission Impossible to Mission Possible” with their research.
Reposted by Dr Pallavi Prasad, MD, DNB ( Nephrology)
Reposted by Dr Pallavi Prasad, MD, DNB ( Nephrology)
T2l
Initiation of 2 first-line agents is still recommended for Stage 2 HTN but there is a new emphasis on using single-pill combinations. One pill goes down easier than two!
What’s your favorite combo pill? Not using combo pills – what’s holding you back? #NephJC
www.thelancet.com/jo...
Initiation of 2 first-line agents is still recommended for Stage 2 HTN but there is a new emphasis on using single-pill combinations. One pill goes down easier than two!
What’s your favorite combo pill? Not using combo pills – what’s holding you back? #NephJC
www.thelancet.com/jo...
September 17, 2025 at 1:34 AM
T2l
Initiation of 2 first-line agents is still recommended for Stage 2 HTN but there is a new emphasis on using single-pill combinations. One pill goes down easier than two!
What’s your favorite combo pill? Not using combo pills – what’s holding you back? #NephJC
www.thelancet.com/jo...
Initiation of 2 first-line agents is still recommended for Stage 2 HTN but there is a new emphasis on using single-pill combinations. One pill goes down easier than two!
What’s your favorite combo pill? Not using combo pills – what’s holding you back? #NephJC
www.thelancet.com/jo...
Reposted by Dr Pallavi Prasad, MD, DNB ( Nephrology)
Check out the insightful VA that makes sense of the updates 🧠
#nephjc
VA by @sejalplakhani.bsky.social
#nephjc
VA by @sejalplakhani.bsky.social
September 17, 2025 at 1:06 AM
Check out the insightful VA that makes sense of the updates 🧠
#nephjc
VA by @sejalplakhani.bsky.social
#nephjc
VA by @sejalplakhani.bsky.social
September 17, 2025 at 1:12 AM
Reposted by Dr Pallavi Prasad, MD, DNB ( Nephrology)
Finally, the concurrent results of the ALCHEMIST trial (www.sciencedirect.co...) also showed that spironolactone did not reduce major cardiovascular events in older, high-risk hemodialysis patients. #NephJC
Infographic by @nephroseeker.medsky.socia
Infographic by @nephroseeker.medsky.socia
September 3, 2025 at 1:52 AM
Finally, the concurrent results of the ALCHEMIST trial (www.sciencedirect.co...) also showed that spironolactone did not reduce major cardiovascular events in older, high-risk hemodialysis patients. #NephJC
Infographic by @nephroseeker.medsky.socia
Infographic by @nephroseeker.medsky.socia
September 3, 2025 at 1:18 AM
Reposted by Dr Pallavi Prasad, MD, DNB ( Nephrology)
The #NephJC editorial team knows that plenty of papers deserve attention between our bi-monthly, full-length discussions
✨Enter #NephJCShorts - quick hits with a critical eye 🦅 on high-impact reads
www.nephjc.com/news/nephjc-...
#MedSky #NephSky
✨Enter #NephJCShorts - quick hits with a critical eye 🦅 on high-impact reads
www.nephjc.com/news/nephjc-...
#MedSky #NephSky
Introducing NephJC Shorts — NephJC
In just over a decade of critical appraisal on NephJC, we have done several experiments. Some of them have worked out phenomenally well, such as the Freely Filtered podcast. Others were not ready for ...
www.nephjc.com
July 2, 2025 at 1:27 PM
The #NephJC editorial team knows that plenty of papers deserve attention between our bi-monthly, full-length discussions
✨Enter #NephJCShorts - quick hits with a critical eye 🦅 on high-impact reads
www.nephjc.com/news/nephjc-...
#MedSky #NephSky
✨Enter #NephJCShorts - quick hits with a critical eye 🦅 on high-impact reads
www.nephjc.com/news/nephjc-...
#MedSky #NephSky
Hi everyone! Good morning from Kerala, God's own country. will be lurking today.
COI: flozinator >> RAASblocker
COI: flozinator >> RAASblocker
June 25, 2025 at 1:44 AM
Hi everyone! Good morning from Kerala, God's own country. will be lurking today.
COI: flozinator >> RAASblocker
COI: flozinator >> RAASblocker
June 25, 2025 at 1:42 AM
Hi everyone! Good morning from Kerala, God's own country. will be lurking today.
COI: flozinator >> RAASblocker
COI: flozinator >> RAASblocker